ArticleBMC ophthalmology2025
Visco-circumferential-suture-trabeculotomy-synechiolysis with phacoemulsification versus phacoemulsification alone for chronic primary angle closure glaucoma.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the surgical outcomes of visco-circumferential-suture-trabeculotomy-synechiolysis (VCSTS) with phacoemulsification compared with phacoemulsification alone for the treatment of chronic primary angle closure glaucoma (PACG). SETTINGS: Mansoura Ophthalmic Center, Mansoura, Egypt.
designRetrospective double armed interventional non randomized comparative study.
methodsA total of 88 eyes (69 patients) with uncontrolled PACG between 2016 and 2022 were subjected to VCSTS with phacoemulsification (Group 1) or phacoemulsification (PE) alone (Group 2). The follow-up period was 24 months. Success was defined as an IOP between 6 and 18 mmHg, with a reduction of at least 30% from baseline with (qualified) or without (complete) antiglaucoma medications (AGMs).
resultsThe mean ± standard deviation ages of the study patients in groups 1 and 2 were 61.1±0.9 and 61.7±0.8 years (p=0.536), respectively. The means ± standard deviations of the preoperative and final postoperative IOP and AGM in groups 1 and 2 were 27.46±0.32 and 28.0±0.3 and 14.15±1.1 and 16.7±0.71 mmHg, respectively (p<0.001), and 3.18±0.07 and 3.2±0.9 and 0.47±1.1 and 1.1±1.5, respectively (p=0.035). The rates of complete success (Kaplan‒Meier) in groups 1 and 2 were 95.3% and 86.7%, respectively (p=0.153). Mild self-limited hyphema was the most common complication in Group 1, with no serious complications reported in Group 2.
conclusionsPhacoemulsification results in a significant and sustained reduction in IOP and the need for AGMs for at least 2 years of follow-up. The addition of VCSTS to phacoemulsification provides a greater reduction in IOP and AGMs and improved surgical success without serious complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.